MARKET

SINT

SINT

SINTX Technologies Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.650
-0.130
-7.30%
Closed 19:41 10/28 EDT
OPEN
1.780
PREV CLOSE
1.780
HIGH
1.782
LOW
1.600
VOLUME
1.74M
TURNOVER
--
52 WEEK HIGH
3.300
52 WEEK LOW
0.2800
MARKET CAP
40.50M
P/E (TTM)
-0.5594
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SINTX Technologies Announces Grant of New U.S Patent For Antibacterial Applications of Silicon Nitride
SALT LAKE CITY, Oct. 28, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), a manufacturer of silicon nitride ceramic for medical and non-medical applications, today announced that the United States Patent and Trademark Office has issued US Patent 10,806,831 covering antibacterial biomedical implants and associated materials. This newly issued patent broadly covers a variety of biomedical implants wherein the Company’s silicon nitride is applied to improve the antibacterial characteristics of the implant. “The antibacterial characteristics of SINTX’s silicon nitride were identified in 2012, and have been confirmed by multiple independent studies. We have developed and tested powders, coatings, and composites of silicon nitride that extend the technology to other material platforms,” said Dr. Sonny Bal President, and CEO of SINTX Technologies. In the biomedical space, beyond monolithic silicon nitride implants that are already FDA-approved, SINTX can now add its material to widely-used biomaterials such as PEEK and titanium. The Company has already developed a composite of silicon nitride and PEEK and expects to launch the product in early 2021.SINTX provides silicon nitride in other forms such as sintered powders and soluble fractions, which expand its technology portfolio yet further. The different forms of silicon nitride allow SINTX to include it in a variety of applications such as fabrics for catch-and-kill face masks that can neutralize respiratory pathogens. The newly-issued patent is an important milestone in SINTX’s strategy to leverage the antipathogenic properties of silicon nitride, and it adds to a growing IP portfolio in that space.About SINTX Technologies, Inc.SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered and ISO 13485:2016 certified manufacturing facility.For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: incorporation of silicon nitride into personal protective equipment and other products may not be safe or effective; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.Business Inquiries for SINTX: SINTX Technologies 801.839.3502 IR@sintx.comMedia Inquiries for SINTX: Amanda Barry Associate Director, Content and PR The Summit Group abarry@summitslc.com
GlobeNewswire · 18h ago
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Oct. 7, 2020: SRAC, SINT, SPI, LEVI, MBOT
Today's 5 Stock Ideas:  Stable Road Acquisition Corp (SRAC) - a special purpose acquisition corporation (SPAC) with a focus on space. Early Wednesday morning, the company announced plans to merge with
Benzinga · 10/07 12:25
SINTX Technologies Develops New Mask Fabric with Silicon Nitride
SN Powder Preparation Silicon Nitride powder preparation at SINTX Technologies. SN Coated PP Fibers SINTX Technologies Silicon Nitride Coating on Polypropylene fibers.SALT LAKE CITY, Oct. 06, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”),
GlobeNewswire · 10/06 14:00
SINTX trades high; progress on 'catch-and-kill' mask manufacture
SINTX Technologies (SINT) +9% PM, updated progress towards the manufacture of a "catch-and-kill" mask that will inactivate respiratory viruses; exposure to silicon nitride has been shown to neutralize several bacterial species and viral
Seekingalpha · 10/06 13:20
MyoKardia, Eidos Therapeutics leads healthcare gainers, Xtant Medical Holdings, Curis among major losers
Gainers: MyoKardia (MYOK) +58%, Eidos Therapeutics (EIDX) +41%, Enlivex Therapeutics (ENLV) +25%, Humanigen (HGEN) +28%, Corvus Pharmaceuticals (CRVS) +26%.Losers: Xtant Medical Holdings (XTNT) -15%, Curis (CRIS) -7%, Immunome (IMNM) -6%, Novus Therapeutics (NVUS) -4%, Sintx Technologies (SINT) -4%.
Seekingalpha · 10/05 14:59
SINTX TECHNOLOGIES APPOINTS MICHAEL MARCROFT AS VICE PRESIDENT OF BUSINESS DEVELOPMENT
SINTX Technologies, Inc. Michael MarcroftSALT LAKE CITY, Oct. 05, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.SINTX.com) (NASDAQ: SINT), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications, announced today that Michael Marcroft has been
GlobeNewswire · 10/05 13:00
DraftKings, AMC Entertainment leads premarket losers' pack
Xtant Medical Holdings (XTNT) -9%.DPW Holdings (DPW) -8% under pressure after hours; launches ATM equity program.AMC Entertainment (AMC) -7%.Sintx Technologies (SINT) -7% on filing for mixed shelf offerings.Iterum Therapeutics (ITRM) -7%.DraftKings (DKNG) -5% on stock offering.
Seekingalpha · 10/05 12:45
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings:Agile Therapeutics (AGRX): $200M.9 Meters Biopharma (NMTR): $200M.Sintx Technologies (SINT): $75M.
Seekingalpha · 10/05 08:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SINT. Analyze the recent business situations of SINTX Technologies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SINT stock price target is 4.250 with a high estimate of 4.500 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 116.76K
% Owned: 0.48%
Shares Outstanding: 24.54M
TypeInstitutionsShares
Increased
0
0
New
6
23.45K
Decreased
2
52.77K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.86%
Healthcare Equipment & Supplies
-3.30%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
B. Sonny Bal
Chief Operating Officer
David O'Brien
Chief Technology Officer
Bryan McEntire
Vice President/Director of Sales/Director of Marketing
Dana Lyons
Vice President - Business Development
Michael Marcroft
Independent Director
Mark Froimson
Independent Director
Eric Stookey
Independent Director
David Truetzel
Independent Director
Jeffrey White
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SINT
SINTX Technologies, Inc., formerly Amedica Corporation, is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company is incorporating its silicon nitride technology into components for use in total hip and knee replacement product candidates. The Company markets and sells its products to surgeons and hospitals in the United States, and certain markets in Europe and South America. The Company produces silicon nitride for use in its commercial products and product candidates in the various forms, such as solid silicon nitride, porous silicon nitride, composite silicon nitride and silicon nitride coating.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SINTX Technologies Inc stock information, including NASDAQ:SINT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SINT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SINT stock methods without spending real money on the virtual paper trading platform.